

Belimumab With Rituximab for Primary Membranous Nephropathy

NCT03949855

Status	RECRUITING
Phase	Phase 2
Sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Enrollment	58 participants

Key Eligibility Criteria

Inclusion (15)

- Subjects must meet all of the following criteria to be eligible for this study-
 - Age 18 to 75 years inclusive
 - Diagnosis of one of the following:
 - Primary MN confirmed by a kidney biopsy within the past 5 years
 - Primary MN that is relapsing following a CR (Section 3.3.1) or PR (Section 3.3.2), confirmed by a kidney biopsy within the past 7 years
- ... and 10 more (see full listing online)

Exclusion (39)

- Subjects meeting any of the following criteria will not be eligible for this study-
 - Secondary cause of MN (e.g., SLE, drug, infection, malignancy) suggested by review of the patient's medical history and/or clinical presentation
 - Rituximab use within the previous 12 months
 - Rituximab use > 12 months ago:
 - With an undetectable CD19 B cell count, or
- ... and 34 more (see full listing online)

Locations (20 total)

University of Alabama at Birmingham School of Medicine: Division of Nephrology, Birmingham, Alabama, United States
University of Arkansas, Little Rock, Arkansas, United States
University of California San Francisco, San Francisco, California, United States
... and 17 more locations